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What is known: Medication non-adherence leads to negative health outcomes. 
Medication adherence is predicted if patients understand the necessity of medica-
tion use to control disease symptoms and progression. It could be expected then, that 
patients with diseases with symptoms which are managed with medications, such as 
chronic obstructive pulmonary disorder or gout, or diseases with high-mortality rates, 
such as cancer, would have higher adherence rates than asymptomatic diseases, such 
as hypertension. However, poor medication adherence remains problematic in both 
symptomatic and asymptomatic diseases. Further work is needed to explore patient 
experiences of medication adherence to understand the link between adherence and 
symptom control.
Objective: To explore patients' lived experiences of medication adherence.
Methods: Participants were recruited from community pharmacies and general prac-
tices. Forty-one semi-structured interviews and three focus groups were used to 
collect data from patients with disease states that had different symptomatic and 
asymptomatic profiles. Inductive thematic analysis was used to identify key parts of 
the experience of using medications.
Results: Participants reported similar experiences of medication adherence despite 
having different disease symptoms. Participants said that they used medications be-
cause it was an expected part of everyday life and that medications ‘must be needed’ 
because they had been supplied, rather than being used for a particular symptom. 
Participants reported short-term episodes of non-adherence were unlikely to lead to 
negative health outcomes but may result in negative social consequences.
Discussion: The findings broaden our understanding of patient experiences of medi-
cation use by indicating patients with symptomatic and asymptomatic diseases share 
similar experiences of medication use. The necessity to use medications appeared to 
come from ‘the system’ of healthcare professionals, family and friends that supply 
and recommend medications.
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1  | WHAT IS KNOWN
Understanding patients' experiences of medication use is important 
as non-adherence to medication for long-term conditions leads to 
increased morbidity and mortality.1-3 For example, poor adherence 
(defined as taking less than 80% of prescribed doses) to anti-hy-
pertensives and statins is associated with approximately 9% of all 
cardiovascular events in Europe.4 The literature presents different 
ways of understanding medication use using biomedical, psychologi-
cal and socioeconomic paradigms.5 For example, medication use has 
been understood using different classifications, such as intentional 
and unintentional non-adherence, or within stages of treatment such 
as initiation, implementation and discontinuation.6-11 Qualitative 
research suggests medication adherence is associated with psy-
chological and sociological factors; such as distrust of medication,9 
the influence of medications on interactions with other people,12,13 
knowledge about the necessity of the medication and fear of side 
effects (the Necessity Concerns Framework),14,15 and self-efficacy.16 
Other evidence suggests interactions with healthcare professionals 
during the supply of medication gives medication use ‘special mean-
ing’, which influences patients to use medications as prescribed.17 
Despite a wide variety of ways of understanding this phenomenon, 
medication adherence remains problematic.
The NCF has obtained wide-spread acceptance and is pervasive 
both within the academic literature as well as professional prac-
tice.8,18-20 Although historically focused on both the necessity to use 
the medication and concerns regarding side effects of using medi-
cation, a meta-analysis of published literature showed that patients' 
experiences of medication adherence are framed by ‘the necessity’ 
to control symptoms, more than concerns about side effects.14 The 
NCF has also translated into the patient sphere, where medications 
are expected to be used when necessary for symptom control.21 
The relationship between adherence, symptoms and the need for 
increased healthcare intervention is well evidenced. For example, in 
respiratory diseases, poor adherence increases hospitalizations and 
morbidity due to an increase in symptoms during exacerbations.22 
The necessity to take the medication as prescribed to control symp-
toms and avoid hospitalization may appear obvious to both patients, 
who are experiencing symptoms, and healthcare professionals sup-
porting patients to manage their symptoms. The NCF has provided 
theory for the development of national and international guidelines, 
as well as interventions to optimize medication adherence.14,23
2  | OBJEC TIVE
As explained by the NCF, the efficacy of a medication to control 
symptoms, such as pain and breathlessness, is thought to motivate 
patients to adhere to medication,13,15,16,24 and represents ‘the ne-
cessity’ to use medication as prescribed. This could mean that for 
diseases that are symptomatic, like respiratory diseases, higher rates 
of medication adherence may be expected than diseases that are 
asymptomatic, like hypertension. However, approximately 50% of all 
medications are not used as intended, in both symptomatic diseases, 
such as chronic obstructive pulmonary disease and gout, and asymp-
tomatic diseases, such as cardiovascular and metabolic disease.25 
Even in conditions that have acute and life-limiting symptoms, such 
as cancer, medication adherence remains problematic.12,15,26,27 This 
suggests, ‘the necessity’ to use medication may not be underpinned 
by a desire for symptom control and may be based on other experi-
ences.28 However, there is limited empirical evidence directly explor-
ing and comparing experiences of medication adherence in patients 
with different symptoms of disease, simultaneously. Therefore, the 
aim of this study was to explore the lived experience of medication 
adherence in patients with symptomatic and asymptomatic diseases.
3  | METHODS
This paper uses the consolidated ‘criteria for reporting qualitative 
research’ (COREQ).29 Ethical approval was awarded for this study 
by an NHS Ethics Committee (Ref 14/SC/0272) and the Research 
Ethics Committee of the School of Medicine, Pharmacy and Health, 
Durham University (Ref ESC2/2014/3).
3.1 | Study design and setting
This research adopted a phenomenological approach.30 This quali-
tative methodology is used to understand the essential compo-
nents of phenomena and transcend previous presuppositions.31,32 
What is new: There were key similarities in experiences of medication adherence in 
patients with different disease states. The negative consequences of short-term epi-
sodes of non-adherence were normalized by healthcare professionals.
Conclusion: Patients with symptomatic and asymptomatic diseases share similar ex-
periences of medication adherence.
K E Y W O R D S
clinical pharmacy, medication adherence, medicine use, qualitative research, symptom control, 
treatment strategies
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This design was chosen as it enabled researchers to set aside a 
priori knowledge via ‘bracketing’ and explore phenomenon in a 
new way to reduce bias from existing presuppositions. Grounded 
theory, case study, narrative approach, phenomenology and eth-
nography are reputable and rigorous methods that could be used 
to study patients' real-world experiences of adherence. Deciding 
which qualitative research approach to use can be difficult. 
Differing philosophical, conceptual or theoretical frameworks or 
ideologies can underpin each approach.33 Aligning the aim of the 
research with the underpinning ontological, epistemological and 
theoretical perspective of the chosen methodology allows a theo-
retically congruent research approach to be adopted.33 Medication 
adherence can be defined and described using a plethora of con-
flicting conceptual or theoretical frameworks and so aligning to 
one of these presented somewhat of a challenge, as epistemologi-
cally it meant giving predominance to one ‘way of thinking’ about 
adherence.5
We felt a narrative approach may subjectively reconstruct the 
phenomenon, potentially devaluing or over valuing our aware-
ness of the chemical nature of medicines and missing the reality 
of using medications that exist in patients' experiences. An eth-
nography, which includes observation of culture-sharing groups, 
was not considered appropriate as just because two people 
share an experience of illness does not infer they share a culture. 
Ethnography would also require a substantial amount of time in 
the field, using observations, which was not practically possible 
for the research team. Grounded theory attempts to produce a 
novel theory, interpreting the experience of the phenomenon to 
generate an explanatory model.33 As a number of explanatory 
models already existed, such as the NCF, we felt that this would 
not ‘fill a gap’ in the literature. Phenomenology, however, rejects 
presuppositions and prejudices about a phenomenon through a 
process known as epoché and seeks to produce a novel descrip-
tion of experience that helps a phenomenon be seen in a new 
way.30 We felt that as pharmacists and a medical sociologist, this 
was a preferred methodology as it helped us identify our previ-
ously held beliefs about adherence and try to find a new way of 
thinking about adherence that captures the reality of patients' 
experiences.
Previous research methods were used to collect large amounts 
of rich data and give direct access to patients' lived experiences, 
perceptions and beliefs.30 Semi-structured, one-to-one interviews 
(n = 41) were conducted at the participants' convenience in their 
homes or at the University. One participant requested his wife was 
present for the interview; however, the remaining interviews were 
conducted with only the researcher and the participant present.
Three focus groups were also conducted, two at the University 
(n = 7 and n = 6 respectively) and a third focus group at a community 
centre (n = 3). A member of the research team conducted the focus 
groups and was supported by other PhD students and post-doctoral 
researchers. Focus groups and interviews were used as two methods 
of data collection (one-to-one and in a group) to expand and validate 
the study findings.32,34
3.2 | Participants and recruitment
Participant recruitment took place in the United Kingdom between 
June 2014 and June 2015. Participants were invited to take part by 
four general practitioners (GPs) and four community pharmacists 
(CPs). GPs and CPs were selected across a range of deprivation 
indices using the Index of Multiple Deprivation Score (IMDS)35 to 
include patient experiences from different socioeconomic settings. 
The IMDS scores areas based on income, employment, education, 
health, crime, barriers to housing and living environment.
Participants were invited to participate by GPs and CPs using a 
purposive recruitment strategy with the following inclusion crite-
ria: adults (≥18 years old); with capacity to give consent; who were 
conversant in English; willing to speak about their experiences of 
medication use and prescribed medication for diabetes, chronic 
obstructive pulmonary disorder, cancer, gout or cardiovascular dis-
ease in the last six months. These five disease states were chosen 
to provide a range of experiences of high- and low-acuity illnesses 
with different symptomatic profiles, to explore similarities and dif-
ferences between disease states, symptom control and adherence. 
GPs and CPs screened their existing health records for patients that 
matched the inclusion criteria, contacted these patients directly and 
obtained consent for patient contact details to be shared with the 
research team. Once contact details had been shared with the re-
search team, we contacted patients to coordinate their participation 
in the study. GPs and CPs also displayed posters that said ‘Have you 
had [disease state]? We are trying to find out about patient experi-
ences of treatment. Ask your [GP/CP] for more information’. Patients 
that expressed an interest were given a Participant Information Pack 
(which included information about the study, the research team, 
how to take part in the study and a consent form). Participants then 
contacted the research team to coordinate their participation in the 
study. The number of people invited to the study that refused to 
participate was not recorded to prevent task overburdening of com-
munity pharmacists and general practitioners. Following the recruit-
ment and completion of interviews, GPs and CPs were asked to use 
the same strategy to recruit additional participants to take part in 
focus groups to validate findings.
Data saturation is reported in the literature at between 6-15 
participants.30,33,36 The research team planned to recruit a minimum 
of 6 participants and up to a maximum of 15 participants for each 
disease state, so that saturation could be reached for each disease 
state sub-group without producing overwhelming amounts of data. 
This equates to a minimum of 30 participants and a maximum of 75 
participants so the research team planned to recruit between 45 and 
55 participants.
3.3 | Data collection
Demographic data relating to age, gender, occupation, post-code 
(to identify level of deprivation) and comorbidity status were col-
lected for each participant and is summarized in Table 1. Interview 
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and focus group topic guides were developed and piloted with a pa-
tient and public involvement (PPI) group (see Supplementary infor-
mation). The questions were adjusted based on feedback from the 
PPI group so that the questions did not make it obvious the research 
was about using medication to control symptoms. During interviews 
and focus groups, participants were asked three open-ended ques-
tions about using medications that enabled them to tell their stories 
of using medication in their own way – rather than being led by the 
interviewer to link their disease or symptoms to medication use. The 
questions were (a) ‘what happened when you were diagnosed?’ (b) 
‘what are your experiences of taking your medicines as prescribed?’ 
(c) ‘what are your experiences of not taking your medicine as pre-
scribed?’ Probing questions were used to explore how medication 
use related to experiences of diagnosis, symptoms and everyday life 
but varied between participants depending on how participants re-
sponded to questions. Interviews were audio-recorded, transcribed 
verbatim and quality checked. We checked interview transcript 
quality by listening to the audio-recording of the interview and 
reading the transcript simultaneously for a random 10% sample of 
interview transcripts. This enables common errors to be identified 
and can prompt further checks on the transcripts if major errors are 
identified. Only minor errors were identified in this sample and these 
were rectified by the research team.
Data saturation, that is, the point at which data sounds famil-
iar with the same experiences appearing over and over again and 
different data do not emerge, was reached at different points for 
different disease states.33,36 Participants that had been invited to 
the study were still interviewed after saturation had been reached, 
to respect their commitment to the study. Following the completion 
of the interviews, three focus groups were conducted to explore, ex-
pand and validate the study findings.32,34 The focus group included 
a brief overview of the results of the study so far and then turned 
to participants to explore their experiences of medication use, using 
the same topic guide as the interviews to prompt discussion. Focus 
groups were audio-recorded, transcribed verbatim and quality 
checked. Interview and focus group transcripts were not returned to 
participants for comment or correction.
3.4 | Data management and analysis
Inductive thematic analysis was conducted after each interview 
and focus group as well as after all data collection was com-
plete.30,33 Transcripts were read line-by-line whilst listening to 
the corresponding audio-recording to create codes. Codes were 
generated, deconstructed and merged until clusters (similar codes) 
and dominant themes emerged. We used a descriptive coding 
technique,37 which included the following steps (a) familiarization 
with the data by re-reading transcripts, (b) ascribing descriptive 
codes to sections of text by summarizing it in a word or noun to 
identify textural and structural data (c) coding phrases inductively, 
clarifying meaning by comparison to other codes within the data 
set (d) clustering codes together to identify common ideas, mean-
ing, emotions and theory, (e) transforming codes into relevant and 
understandable themes, by combining clusters and reflecting to 
ensure the meaning of the code is not lost. All members of the 
research team contributed to analysis using manual coding and 
NVivo12. Thematic analysis, underpinned by phenomenology, was 
used at it enabled analysis to go beyond the content of interviews, 
identifying relationships between key parts of participant expe-
riences.30,33,37 Phenomenology requires researchers to epoché or 
‘bracket’ prior to analysis to identify prejudices, biases and a priori 
knowledge.30 Bracketing helped the team critique their analysis 
against identified prejudices and adds rigour to the analysis, as it 
forces researchers to interrogate codes and themes to ensure the 
analysis is inductive and based on data, rather than previously held 
beliefs. We bracketed by holding regular meetings to explore past 









≥80 years 7 12%
70-79 years 20 35%
60-69 years 17 30%
50-59 years 11 19%


















Note: The data indicate that the sample for the study were mostly 
males, who were retired. Participants with cardiovascular disease 
were over-recruited compared to other disease groups. There was a 
good spread of participants from areas of high, intermediate and low 
deprivation. The majority of people in this study were over 60 years old.
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and present beliefs relating to medication adherence, pharmacists, 
patients, different disease states and other concepts with trusted 
colleagues within and external to our School.38 Memos were also 
made during the analysis which were discussed during meeting 
and reflected upon.38
Rigour was also added throughout the analysis as preliminary 
findings were presented at research group meetings with academic 
pharmacists and qualitative researchers, who helped scrutinize the 
coding. Using computer coding also added rigour to the analysis as 
it established a date-tracked audit-trail, enabling researchers to re-
flect on how codes and themes were constructed over time and by 
whom.33 Participants and a PPI group also provided feedback on the 
findings at a research engagement event, which further validated 
the findings.
Data from focus groups were analysed using the same approach 
as the interviews. Findings from the focus group data were com-
pared and contrasted with findings from interview data to validate 
interview findings.
3.5 | Research team and reflexivity
The research team included three clinical pharmacists (APR, AT and 
AKH) and a medical sociologist (KJ). The research team and par-
ticipants did not have a relationship prior to the study. Participants 
were informed that the interviewer was a doctoral student and a 
pharmacist, but that no clinical advice could be given during the 
interview, no information would be passed to their usual care team 
about non-adherence and that we were looking for open and hon-
est accounts of experiences of using and not using medications 
as prescribed. This was done to reduce the chance of bias that 
participants would only share ‘positive’ or pro-social experiences 
of using medications.39 The management of the professional ethi-
cal and legal tensions this created are reported in detail in another 
paper.40
4  | RESULTS
Forty-one participants took part in one-to-one interviews. Interviews 
lasted between 67 min and 46 s and 115 min and 29 s, with a mean 
interview length of 90 min 12 s. Sixteen participants took part in 
focus groups. Focus groups lasted between 87 min 57 s and 112 min 
23 s. Focus Group 1 had seven participants, Focus Group 2 had six 
participants and Focus Group 3 had three participants. We appreci-
ate Focus Group 3 is a very small group; however, we still wanted to 
include the data from this group as they were quite a vibrant group 
and although not ideal in terms of numbers of participants, it did 
work well. Demographic details of participants are summarized in 
Table 1 for further information. Data was synthesized and findings 
of the analysis are presented below.
Three themes were identified that represent key components 
of the experience of medication adherence in each of the different 
disease groups. These were (a) identification, (b) necessification and 
(c) routinization and adaption.
4.1 | Theme 1) Identification
Participants described experiences of ‘getting to know’ their medi-
cations through a process of identification.
well you have to get to know your medicines initially, 
because when they first give you them, you have no 
idea what they are or what they’re for. I mean obvi-
ously you know what they are, they’re medicines and 
they’re for something, but really it’s just like you know 
they exist and people take them when they’re told 
to, but you don’t actually know the individual ones 
you’re getting, then gradually you start to get to know 
them then in the end you know them quite well really, 
they’re a part of your life. - 
P8, cardiovascular disease
The identity of medications was based on experiences of the action 
of medications as physical sensations in the body which confirmed that 
expectations of the participants to use medication had been fulfilled.
over time you get to know them really well, because 
they do things to you, so for example that one [holds 
up salbutamol] I know is really good, because when I 
take it, I can feel it settling on my tongue, so I know 
it’s definitely gone in and that sort of calms me down, 
because I know I’m doing what she [the carer] wants 
and what the doctors wants and it just feels right. And 
that feeling doesn’t go away, I mean now when I use 
it, to be honest I can’t tell if it’s going in or not, but it 
feels like I’m doing what I should be doing, I’m doing 
my bit, so to speak because its doing its bit - 
P32, chronic obstructive pulmonary disease
In the extract below, the participants' expectations of the action of 
medications were based on prejudices about the physical character-
istics of the medication, for example, the size and shape, where small 
dosage forms were thought to be less harmful, and information from 
healthcare professionals and friends.
The ones they gave me were only very, very small, 
and even though the doctor was saying they’re very 
good, I’d heard from a friend they were actually quite 
nasty, not very kind to your stomach, so I was a bit 
unsure about what they were really like at first, but 
then once I’d taken them, they did upset my tummy 
so I knew they were going in, but I felt that sense of 
relief that, you know, things will get better now, and 
because they were only small things, you know even 
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though they are a bit nasty, they’re only small so what 
harm can they really do?- 
P1, gout
Medications that created physical sensations that were expected, 
that is, side effects, had characteristics such as ‘strength’ and ‘good 
workers’.
it’s quite an important characteristic of my medica-
tions, that you know, they do do something, because 
I know they’re doing it because of the side effects, so 
my [medication] makes my tummy go queasy. So, al-
though my symptoms are still there, and to be honest, 
I’m not sure the medication knows where the problem 
is, because the medication’s working on my stomach, 
so if it’s doing something there, who am I to say it’s 
not doing something somewhere else? I mean I can 
still feel the problem I went in for, it’s still there, the 
symptoms are still there, but if you get told to take it 
and then you can feel it doing something, even if you 
don’t understand what it’s doing really or you think 
it’s doing something in the wrong place, you’re going 
to keep taking it because it is doing something, I mean 
just like you would expect it to because that’s what 
people say isn’t it, you take the medication because 
it needs to work in your body. So, you know that that 
medication, itself, is a good worker, it’s got enough 
oomph [strength] to do something, it’s behaving as it 
should so I take it as I should 
P29, diabetes
The experience of physical effects and abstract characteristics 
that participants heard about medications created the identity of the 
medication, as having ‘oomph’ interpreted in the extract above as 
strength, which re-assured medications were ‘behaving’ as expected. 
If medications ‘behaved’ as expected (i.e., caused a physical sensation) 
participants responded by ‘behaving’ as they were expected to, using 
medication as prescribed.
This was reinforced when medications did not ‘behave’ as ex-
pected, that is, did not cause physical effects, and made the partici-
pant feel as if they had not taken anything.
The medications they give me initially didn’t really do 
anything so I wasn’t taking them, I mean, they might 
have done something, but I didn’t feel like they were. 
I mean I got the impression from the people that gave 
me them that it was a bit pointless taking them to be 
honest, and other people with cancer I’d spoken to 
had said they didn’t feel anything when they took it. 
But I thought, I’ll give this a go, it might work for me, 
but then to be honest with you, I think I took a hand-
ful, but nothing happened. So if you’ve been given a 
medication, and you identify that it’s a bit of a dud 
one, that doesn’t really work, it makes you feel like, 
like you shouldn’t put the work in to take it, if it’s not 
going to do the work once you’ve taken it. So, I didn’t 
bother with the rest after that. At the end of the day, 
I still had cancer and if I couldn’t feel them doing any-
thing what was the point? - 
P35, cancer
Participants that could not feel the physical effects of the medica-
tion, identified these medications as weak or not working and were not 
motivated to take medications as prescribed.
4.2 | Theme 2) Necessification
Participants reported getting to know their medications over time; 
however, the ‘need’ to use medications was inherent in being sup-
plied a medication.
If I was given a medicine then I’d have taken it, be-
cause that’s just what you do isn’t it, you’re given a 
medication for a reason, so you take it – 
P41, cancer
The reason medications were needed could vary from the pre-
scribed indication; for example, one participant was prescribed 
co-codamol for pain relief but used them nightly as an anxiolytic.
I take […] two co-codamol […] they are my little friends 
on a night-time, I need to take them because on a 
night it relaxes me, 
P24, chronic obstructive pulmonary disease
Using medications as they were prescribed was described as a ne-
cessity to deal with everyday 21st century life.
I mean using medicines now, in the 21st century, it’s 
just part and parcel of life isn’t it? Even from being a 
young ‘un you need to use stuff, because they help 
don’t they? I mean even now my grandkids they’re 
taking medications every day, because it keeps them 
going you know. The world is tougher than it used to 
be now, you know people working the weekends, in 
the night, always attached to a screen, so the wear 
and tear of everyday life, that needs to be smoothed 
out with a pill. And even you know, the kids when they 
go clubbing, they take pills don’t they? I mean they’re 
probably not meant to, but they take pills the next 
day to deal with the hang over don’t they? So really, 
for me, when I was told I was going to have to take a 
medication, I just felt like, yeah okay, this is normal. It 
wasn’t a big deal or anything. – 
P6, diabetes
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Other participants described feeling that they had no choice 
but to ‘take medication’ and although this was an expected part of 
everyday life, it was needed to maintain survival. One participant 
simplified his interaction with pharmaceutical products as binary, life 
or death.
if you want to live, you’ve got to take them…[…]…the 
box is there, I know it’s there and I know I have to 
take them, it’s either take them or die, simple as that 
isn’t it? 
P18, chronic obstructive pulmonary disease
That using medications was experienced as a key part of survival, 
not using medication as prescribed was considered selfish because 
of the social implications poor health and death may have on people 
around them.
for somebody that is of a reasonable age who doesn’t 
want to take tablets to help them have a normal a life 
as possible with the aid of tablet, I just don’t see any 
reason why they’re just not going to do it. […] espe-
cially if they’re of an age where people are dependent 
on you, like if you’re the husband and you’re married 
with a wife and kids and what have you, these people 
don’t deserve to be left on their own with me being 
selfish 
P26, diabetes
The majority of participants conceptualized the necessity of med-
ication adherence as a function of their survival in relation to their so-
cial life.
I don’t think they give you these tablets unless you 
need them… and if you stop taking them then you’re 
putting your life back at risk, therefore if anything 
happens then you’re putting your life back in risk, 
it’s the individual person that then has to deal with 
the consequences of that on their family or friends 
or pets or whatever. It’s up to them, you can’t twist 
their arms and put it down their throats, but I don’t 
think they would give you them if you didn’t need 
them 
P7, cardiovascular disease
This suggests that despite variation in symptoms, morbidity and 
mortality between participants with different diseases, the shared a 
necessity to use medications which came from medications being 
supplied.
you must need to take them, otherwise why would 
they give you them? I mean I don’t know what it’s 
doing inside me or why I need it really, but if I didn’t 
need it they wouldn’t give it to me would they? They 
only give you them cause you need them and to have 
to take them, 
P22, gout
Being told medications were needed by ‘the system’ meant partici-
pants used medication, even if they didn't really want to.
I wouldn’t say you come resigned [sic] but you just 
come to taking the tablets even if you don’t really 
want to, because the whole system is telling you you 
need to take them, you get letters, you get texts to 
pick them up, you see people on the telly taking their 
medications and that makes you think oh I need to 
remember to take mine as well 
P26, diabetes
However, participants reported changing their views about the ne-
cessity of taking medications as prescribed, based on the reaction of 
healthcare professionals.
Well in the beginning I would worry about not taking 
them, like if I missed one or ran out or there were peo-
ple around us if we were on holiday and I couldn’t take 
it front of them, I used to panic a bit about it but one 
time I’d forgotten for a couple of days, maybe three or 
four days, and I went to the pharmacist and they said 
that actually, it’s not a problem, just carry on taking 
it. And he was so blasé about it that it made me think 
well they can’t be doing that much good can they? So 
now if I miss them, I don’t worry. I suppose if I said to 
him I want to come off them permanently, he’d be a 
bit more bothered, because then he’d lose a customer, 
but in all seriousness I don’t worry about not taking 
them over a couple of days. If it was long-term, then 
I think I do need them, because obviously the NHS is 
paying for it for a reason isn’t it, but really, in the short 
term, here and now, I’m not really sure why I need to 
take them, but I do. 
P17, cardiovascular disease
One participant reported he no longer felt any medications were 
needed because ‘they’ (the doctors and nurses) in the system, changed 
his therapy which made him doubt the need to take any medications 
at all.
to tell you the truth, it doesn’t make your feel any dif-
ferent if you take it or you don’t, you still have dia-
betes either way so I don’t see the point in taking it 
all the time. But then when she said she wanted to 
stop the injections and put me on something else, 
otherwise I’d end up dead, and I just thought hold on, 
you’ve told me before it’s fine and now you’re saying 
I’m going to die? It just makes you doubt what they’re 
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all saying to you, the nurses and the doctors, if they 
can stop, and swap, and change your medicines all the 
time, do you really need them in the first place? So, I 
talked about it with the wife and together we decided 
just to stop them, because it’s no fun really. 
P02, diabetes
The participants in this study experienced a shared necessity of 
using medications despite differences in their disease symptoms. The 
necessity to use medication for these participants was inherent in the 
products that were supplied. The system (doctors, nurses, pharma-
cists, friends and family) made participants feel that their medication 
was inherently needed; however, dissonance in the system meant the 
necessity of using medications could be lost, and resulted in experi-
ences of non-adherence.
4.3 | Theme 3) Routinization and adaption
Over time the necessity and identity of medications appeared to be-
come a secondary part of the experience of medication use, replaced 
with routine and automated interactions between the patient and 
the product.
The regular use of medication was present in participants with 
chronic, asymptomatic diseases such as cardiovascular disease.
well I take them at night, every night, that’s my habit, 
my routine. It’s like getting ready for bed on a night, 
having supper and things like that, you do it the same 
every day, like brushing your teeth, it just part of the 
habit you get in to, It’s not like I take it for a particular 
reason, you know I don’t think oh I’m feeling unwell 
I better take my medication, I just take it routinely 
come rain or shine, because that’s what you’re sup-
posed to do 
P7, cardiovascular disease
This meant medication use became habitual.
I didn’t want to take them at the beginning, but with 
reluctance it was just habit forming. I had to get into 
the habit of taking them and once I’d done that, I had 
no problem taking them, it was just automatic, second 
nature 
P3, diabetes
The routine use of medications was also experienced by partici-
pants with acute, symptomatic illnesses.
I don’t see it as a problem, I mean lots of people like 
routine anyway don’t they? If they get into it then you 
just do it 
P5, gout
Participants with significant and potentially life-limiting illnesses, 
such as cancer, have similar experiences of routinely using medications.
I think you just get into the routine and then it be-
comes second nature to you to be truthful 
P40, cancer
Physical experiences of the action of the medication that helped 
participants initially identify if the medication was working became 
secondary once habitual medication use was established. Rather 
than focusing on what medications did physically, participants re-
ported trusting that the medication was ‘doing what it was supposed 
to’.
It doesn’t really bother me, I just take them you know, 
a habit, put it that way, a habit you just automatically 
take them and hope that they’re going to do their 
work, I can’t say that I’m that keen on taking them 
and I don’t really know what they’re doing inside me, I 
don’t feel them doing anything so much anymore, but 
I carry on taking them anyway because it’s part of my 
routine now 
P20, gout
These data suggest that routine becomes an important part 
of medication adherence once participants had ‘got to know’ their 
medication worked, even if they could no longer feel the medication 
working. Although the necessity to use medications was still inherent 
because medications were supplied, one participant described he felt 
his need to take medications was reinforced as using medications be-
came a part of life.
I need to take them because it’s part of my routine, if I 
didn’t have to get up to take them, I probably wouldn’t 
get up I don’t think. It, in a way, in the beginning, you 
take them because someone gives them to you and 
so you feel like it must be something you’ve got to do, 
you know, to survive as it were, but then after a while, 
it doesn’t feel like they’re keeping your alive so much 
as using them is part of life, so if you didn’t have to go 
to the doctor, get the prescription, pick it up, count 
them out, put them in the box, go for the blood tests, 
forget to take them, remember to take them, have the 
side effects and all that, that actually life itself would 
be quite different, so they keep you alive but they also 
give you a life, because if it wasn’t for all the work 
and people involved in getting them, I don’t think I’d 
speak to a soul, I don’t think I’d have very much of 
a life at all. It keeps you active, I mean, I’m not very 
old and I’ve never really worked, but I think it’s a bit 
like work, keeping yourself in the routine to take your 
medication – 
P12, cardiovascular disease
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However, other participants described an alternative view that 
included episodes of short-term non-adherence within their medica-
tion-taking routines. For example, missing one or two doses or ‘a few 
days’ worth of medication was not perceived negatively and had little 
impact on short-term or long-term symptoms or survival.
oh yeah, but what I don’t do, I won’t take them if I’m 
missed them in the morning I won’t take them late 
on of an evening if I’m going to have to take them 
of a night-time, because that, in effect, on some of 
them is doubling them up – if I’ve survived that long 
[without them], I’ll survive another couple of hours 
[laughing]- 
P3, diabetes
Participants reported adapting their medication use routine to 
accommodate missed doses, by minimizing the detrimental effects of 
non-adherence.
I did panic a little bit and I don’t know why I should, 
but you know you think, is it going to make any differ-
ence if I miss one? Well you know it’s not really, […] as 
time passes, you get to be a little bit more, ‘calm your-
self down a little bit, missing one tablet isn’t going to 
make any difference’ [laughing] I did worry at the be-
ginning you know, if it would have any effect on me if I 
did forget but I’d only forgotten for about six hours so 
really, you know, it’s a bit silly you know, looking back 
on it now you know, ‘get a grip’ [laughing] 
P36, cancer
Adaptations to medication routines appeared to be influenced by 
social life (e.g., interactions with other people).
I’ve got somebody round and we’re talking, the [re-
minder] goes off and I think ‘oh tablets’ I’ll remem-
ber that but of course they’re there for another hour 
maybe, I’m still talking, and when [the person] goes 
I haven’t thought anymore about the tablets so the 
alarm is pointless [laughing] yeah, I do [miss them], I 
wouldn’t say I do it often, but I’ve certainly done it 
several times - 
P9, cardiovascular disease
However, patients described that beyond a few hours or a few 
days, non-adherence may become socially problematic.
to be honest with you, it doesn’t make a bit of differ-
ence if I miss a couple of doses, you know, I mean, 
I know I’ve missed them or I’ll work out I’ve missed 
them, but as long as the missus doesn’t find out, it’s 
not a problem. It’s not like it has an effect really if I 
only miss a couple, I think more than that, like if I just 
stopped taking it, I think the missus would be after 
[laughing] - 
P32, chronic obstructive pulmonary disease
This suggests that patients' experiences of medication adherence, 
including short-term missed doses, are focused on social consequences 
rather than symptomatic ones. This establishes routine non-adherence 
as a constitutive part of patients’ experience of medication adherence.
5  | DISCUSSION
Participants described experiences of identifying or ‘getting to 
know’ their medications based on the action of the medication on 
their bodies; on unique physical characteristics of the products 
(e.g., colour, size, shape) and on abstracted, subjective attributes, 
such as kindness and nastiness. Using medications was an expected 
part of life in the 21st century. The necessity to use medications 
came from ‘the system’ – doctors, pharmacists, friends and family, 
that supplied, recommended or expected medications to be used as 
prescribed. Over time, participants established routine medication-
taking practices, which reinforced the necessity to use medications 
as part of everyday life, to give life structure. Routines included 
short-term episodes of non-adherence with consequences that were 
social, rather than health outcome related. The findings indicate that 
participants with different disease symptoms shared key parts of the 
experience of using medications based on the physical effect of the 
medication on their bodies and the social effects of medication use 
on the people and healthcare professionals around them.
These findings provide evidence that adherence is experienced 
similarly in patients with different diseases and is a phenomenon 
of necessity.14,23,41 This presents additional support for work that 
argues necessity, rather than being based on symptom control or 
disease progression, is inherent in the medications themselves when 
they are supplied by health professionals.17 This adds further to 
existing work which suggests the social status of pharmacists (and 
other healthcare professionals) may be central to the necessity of 
a medication, transferring ‘special social meaning’ to using medica-
tions during the supply process.17 However, participants in this study 
experienced medication non-adherence when there was dissonance 
with information from healthcare professionals in ‘the system’. This 
suggests that in addition to repeated exposure to healthcare pro-
fessionals, the consistency of information provided to patients by 
healthcare professionals may be an important part of medication 
adherence. The development of interventions that lead to sustained 
improvements in medication adherence may need to focus on re-
peated and consistent exposure to healthcare professionals within 
‘the system’ that supplies medications, to identify ways to ensure 
that medication use retains its ‘special meaning’.
Our findings support existing qualitative research which de-
scribes adherence as a function of relationships between peo-
ple,9,12,17 The ‘special meaning’ ascribed to medication from 
healthcare professionals involved in supplying them may also come 
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from others – such as family, friends, newspapers and the internet. 
In participants in this study, the social basis of adherence appeared 
to be more important than the health consequences of non-adher-
ence. This suggests exposure to information about medication use 
may not necessarily need to relate to health consequences, but 
rather could relate to social norms, trends or impact. Further work is 
needed to explore patients’ experiences of adherence in relation to 
exposure to information about medication use and how this informs 
patterns of adherence or non-adherence.
6  | WHAT IS NE W
There were key similarities in experiences of medication adherence 
in patients with different disease states. The routinization of missed 
doses by participants in this study is concerning. For healthcare pro-
fessionals and policy makers, the therapeutic and socioeconomic 
consequences of medication non-adherence are problematic.17,32,35 
Non-adherence increases rates of mortality in multiple disease 
states.2,3,22 Yet the participants in this study shared the experience 
that non-adherence was not problematic and would not have nega-
tive health outcomes. There is limited evidence of the minimum level 
of adherence to achieve therapeutic outcomes. However, the nor-
malization of medication non-adherence could lead to lower drug 
serum concentrations, contributing to poorer health outcomes.42 In 
this study, participants reported not observing the physical effects 
of missed doses contributed to the normalization of non-adherence. 
Additionally, participants in this study reported the minimization of 
short-term non-adherence meant non-adherence could become rou-
tine. Health professionals should therefore try hard not to minimized 
non-adherence and to link non-adherence to missed therapeutic 
outcomes; utilizing drug serum levels where possible to indicate 
the physical effects of non-adherence; emphasizing the necessity 
of medication use as prescribed and the consequential benefits on 
health outcomes.
Both interview and focus group data was collected which 
strengthen the transferability and validity of findings, as what 
people said in a one-to-one interview settings was the same as 
a group setting. However, the findings may be limited as partici-
pants were all from one geographical location and of one cultural 
group (white British), so findings may not be generalizable to other 
geographical and cultural areas. Further work should explore the 
experience of adherence across cultural contexts in different dis-
ease states.
7  | CONCLUSION
The aim of this study was to explore the lived experience of medi-
cation adherence in patients with symptomatic and asymptomatic 
diseases. Medication adherence was an expected and routine part of 
everyday life in the 21st century for patients with both symptomatic 
and asymptomatic diseases, with the necessity to use medications 
based on ‘the system’ of healthcare professionals, friends and family 
that supported medication use. Participants in this study reported 
medication non-adherence had negative social consequences, rather 
than negative health outcomes, and that these experiences were 
normalized by healthcare professionals. Further work is needed to 
validate and generalize these findings, as medication non-adherence 
has considerable negative impacts on health and well-being which 
may be being undermined. Healthcare professionals must carefully 
consider their role in normalizing episodic short-term non-adherence 
and highlight the important positive health outcomes of medication 
adherence.
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